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ABSTRACT
The mevalonate (MVA) pathway is involved in cell proliferation.
We investigated drugs acting at different enzymatic steps on rat
aorta smooth muscle cell (SMC) proliferation. Competitive in-
hibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase
(0.1–10 mM) dose-dependently decreased (up to 90%) SMC
proliferation. This effect was prevented by 100 mM MVA, 10 mM
all-trans farnesol (F-OH) and 5 mM all-trans geranylgeraniol
(GG-OH), precursors of protein prenyl groups, but not by 2-cis
GG-OH, precursor of dolichols, squalene and ubiquinone. The
same inhibitory effect was obtained with 6-fluoromevalonate
(1–50 mM), an inhibitor of MVA-pyrophosphate decarboxylase.
Partial recovery of cell proliferation was possible by all-trans
F-OH and all-trans GG-OH, but not MVA. Squalestatin 1 (1–25
mM), a potent squalene synthase inhibitor, blocked cholesterol
synthesis and slightly inhibited (21% decrease) SMC prolifera-
tion only at the highest tested concentration. NB-598 (1–10
mM), a potent squalene epoxidase inhibitor, blocked choles-
terol synthesis without affecting SMC proliferation. Finally, the
benzodiazepine peptidomimetic BZA-5B (10–100 mM), a spe-
cific inhibitor of protein farnesyltransferase, time- and dose-
dependently decreased SMC proliferation (up to 62%) after 9
days. This effect of BZA-5B was prevented by MVA and all-
trans GG-OH, but not by all-trans F-OH. SMC proliferation was
not affected by the closely related compound BZA-7B, which
does not inhibit protein farnesyltransferase. Altogether, these
findings focus the role of the MVA pathway in cell proliferation
and call attention to the involvement of specific isoprenoid
metabolites, probably through farnesylated and geranylgerany-
lated proteins, in the control of this cellular event.
Several studies suggest that the MVA pathway plays a role
in cell growth (Goldstein and Brown, 1990; Habenicht et al.,
1980; Chen, 1984; Fairbanks et al., 1984). MVA is intracel-
lularly synthesized from HMG-CoA, and this process is cat-
alyzed by HMG-CoA reductase, the rate-limiting enzyme in
this pathway (Goldstein and Brown, 1990). MVA metabolism
yields a series of isoprenoids that are vital for diverse cellular
functions, ranging from cholesterol synthesis to growth con-
trol (Goldstein and Brown, 1990; Maltese, 1990; Grunler et
al., 1994; Glomset et al., 1990). The exposure of cultured cells
to competitive inhibitors of HMG-CoA reductase (statins),
such as lovastatin, compactin or simvastatin not only blocks
the biosynthesis of MVA but, in addition, pleiotropically in-
hibits DNA replication and cell cycle progression (Habenicht
et al., 1980; Fairbanks et al., 1984; Doyle and Kandutsch,
1988; Sepp-Lorenzino et al., 1991). These effects of statins
are prevented by the addition of MVA to the culture medium,
but not by the addition of cholesterol, the major end-product
of the MVA pathway (Habenicht et al., 1980; Fairbanks et al.,
1984; Doyle and Kandutsch, 1988; Corsini et al., 1991). These
observations have been interpreted to indicate the involve-
ment of nonsterol derivative(s) of MVA for cellular prolifer-
ation to proceed. Potential MVA-derived products (Goldstein
and Brown, 1990; Maltese, 1990; Grunler et al., 1994;
Quesney-Huneeus et al., 1983) candidates for this role in-
clude: isopentenyl adenosine, present in some types of trans-
fer RNAs; dolichol phosphates, required for glycoprotein syn-
thesis; polyisoprenoid side chains of ubiquinone and heme-a,
involved in electron transport. Studies with the BHK cell line
suggest that isopentenyl adenosine is able to overcome the
inhibitory effect of statins on DNA synthesis (Quesney-
Huneeus et al., 1980). Even though in other cell systems, the
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ability of isopentenyl adenosine to rescue proliferation has
not been confirmed (Perkins et al., 1982; Sinensky and Logel,
1985; Larsson and Zetteberg, 1986; Munro et al., 1994),
Faust and Dice (1991) found that the expression of protein
i6A26, which contains isopentenyl adenosine, decreases dur-
ing lovastatin treatment and increases after subsequent
MVA treatment and restoration of cell proliferation. Wejde et
al. (1993) found that high concentrations of dolichol cause a
slight restoration of DNA synthesis in lovastatin-treated
cells; there is also evidence for a critical role of protein gly-
cosylation in the control of cell proliferation (Doyle et al.,
1993; Carlberg et al., 1994). None of these compounds, how-
ever, is consistently able to restore proliferation when endog-
enous MVA metabolism is suppressed. The potential impor-
tance of early intermediates in the MVA pathway, rather
than more distal isoprenoid metabolites, has also been pro-
posed as a critical regulator of cellular proliferation (Cuth-
bert and Lipsky, 1991).
Recently, several proteins post-translationally modified by
the covalent attachment of MVA-derived isoprene groups
(prenylation), farnesyl-PP or geranylgeranyl-PP, have been
identified (Maltese, 1990; Glomset et al., 1990; Sinensky and
Lutz, 1992; Casey, 1992). These proteins must be prenylated
as a prerequisite for membrane association, which, in turn, is
required for their function (Glomset et al., 1990; Glomset and
Farnsworth, 1994; Jakobisiak et al., 1991; Farnsworth et al.,
1990). Identification of some of them, nuclear lamin B (Farns-
worth et al., 1989), ras proto-oncogene (Casey et al., 1989;
Hancock et al., 1989) and the g subunit of heterotrimeric
GTP-binding proteins (Glomset and Farnsworth, 1994; Ya-
mane et al., 1990, 1991; James et al., 1996), raises the pos-
sibility that nonsterol products of the MVA pathway neces-
sary for cellular proliferation may be one or more prenylated
proteins. For this reason, the two classes of enzymes that
catalyze the addition of a prenyl group to proteins, PFTase
and PGGTase I and II (Casey and Seabra, 1996; Yokoyama
and Gelb, 1993; Chen et al., 1991; Zhang et al., 1994), have
gained attention as novel targets (Tamanoi, 1993; Gibbs et
al., 1994; Reiss et al., 1990; Hancock, 1993) for the develop-
ment of agents aimed at controlling abnormal cell growth,
such as myocyte proliferation under atherogenic conditions
or tumor development (Ross, 1993; Lowy and Willumsen,
1995). Among the prenylated proteins, much attention has
been focused on p21 ras for its key role in the pathophysiol-
ogy of cell proliferation (Lowy and Willumsen, 1993; Boguski
and McCormick, 1993). Because farnesylation of p21 ras is
required for its mitogenic activity, an intensive search for
PFTase inhibitors is underway (Gibbs et al., 1994; James et
al., 1993; Bishop et al., 1995; Kohl et al., 1995). The interfer-
ence of lovastatin with cell cycle progression in carcinoma
T24 cell line could be attributed to inhibition of farnesyl-PP
biosynthesis and thereby isoprenylation of ras proteins
(Jakobisiak et al., 1991). In other cell systems, however, the
inhibition of cell growth by lovastatin is independent of ras
function (DeClue et al., 1991).
In conclusion, the identity of the nonsterol derivative(s) of
MVA required for cell growth remains to be elucidated, and
the role of prenyl-modified protein(s) in DNA synthesis and
cellular proliferation needs to be further explored.
Our observations that all-trans F-OH or all-trans GG-OH
can prevent the statin-induced inhibition of SMC growth in
the absence of other isoprenoids (Corsini et al., 1993, 1995a),
together with recent studies showing that both all-trans
F-OH and all-trans GG-OH are readily incorporated into
cellular proteins (Corsini et al., manuscript in preparation;
Crick et al., 1994; Danesi et al., 1995), support the potential
role of prenylated protein(s) in the control of cell prolifera-
tion.
In the present study, we have further addressed this mat-
ter by investigating the effect of drugs affecting diverse en-
zymatic steps of the MVA pathway on arterial SMC prolifer-
ation with the final goal of identifying potential MVA
products involved in the control of cell proliferation.
Methods
Eagle’s MEM, trypsin ethylenediaminetetraacetate, penicillin
(10,000 U/ml), streptomycin (10 mg/ml), tricine buffer (1 M, pH 7.4)
and nonessential amino acid solution (1003) were purchased from
Gibco (Grand Island, NY), and FCS was from Mascia Brunelli (Mi-
lan, Italy). Disposable culture flasks and Petri dishes are from Corn-
ing Glassworks (Corning, NY), and filters are from Millipore (Bed-
ford, MA). [2-14C]Acetate, sodium salt (58.9 mCi/mmol) and
[1a,2a(n)-3H]cholesterol (47.7 Ci/mmol) are from Amersham (Amer-
sham Place (Buckinghamshire), UK). Isoton II was purchased from
Coulter Instruments (Milan, Italy). All-trans F-OH, ubiquinone and
squalene are from Sigma (St. Louis, MO). All-trans GG-OH was
kindly provided by Prodotti Roche (Milan, Italy). 2-cis GG-OH was
prepared by oxidation of all-trans GG-OH with MnO2 to yield a
mixture of isomeric aldehydes which was purified by preparative
thin-layer chromatography on silica gel plate F254 (Merck, Milan,
Italy) with use of hexane/diethyl ether (7:3). The 2-cis aldehyde was
converted to 2-cis GG-OH by reduction with sodium borohydride in
ethanol, and the product was purified as for the aldehyde. Silica Gel
G thin-layer chromatography products are from Merck (Milan, Italy).
All reagents are analytical grade.
Drugs. Simvastatin in its lactone form, provided by Merck, Sharp
& Dohme Research Laboratories (Woodbridge, NJ), was dissolved in
0.1 M NaOH to give the active form, and the pH was adjusted to 7.4
by adding 0.1 M HCl. Pravastatin, provided by Bristol Myers Squibb
Pharmaceutical Research Institute (Princeton, NJ) and cerivastatin,
provided by Ricerca Bayer Farmacologia (Milan, Italy), were dis-
solved in 0.15 M NaCl, and their solutions were sterilized by filtra-
tion. Racemic fluvastatin, provided by Sandoz Prodotti Farmaceutici
(Milan, Italy), and L 645–164, provided by Merck, Sharp & Dohme
Research Laboratories (Woodbridge, NJ), were dissolved in ethanol.
6-Fmev was prepared according to Quistad et al. (1981) and was
dissolved in ethanol. Squalestatin 1, provided by Glaxo (Greenford,
UK), was dissolved in water; NB-598, provided by Banyu Pharma-
ceutical Co., Ltd. (Tsukuba, Japan), was dissolved in dimethyl sul-
foxide. BZA-5B and BZA-7B, provided by Genentech Inc. (South San
Francisco, CA), were dissolved in dimethyl sulfoxide/dithiothreitol
according to James et al. (1993).
Cell cultures. SMC were cultured, according to Ross (1971), from
the intimal-medial layers of aorta of male Sprague-Dawley rats
(200–250 g). Cells were grown in monolayers at 37°C in a humidified
atmosphere of 5% CO2 in MEM supplemented with 10% (v/v) FCS,
100 U/ml penicillin, 0.1 mg/ml streptomycin, 20 mM tricine buffer
and 1% (v/v) nonessential amino acid solution (Corsini et al., 1991).
The medium was changed every third day. Cells were used between
the fourth and tenth passages. SMC were identified for growth
behavior, morphology and use of monoclonal antibody specific for
a-actin, the actin isoform typical of SMC (Skalli et al., 1986). The
cells grew out of explants after 12 to 16 days, piled up after conflu-
ence and contained numerous myofilaments and dense bodies, as
observed by transmission electron microscopy (Ross, 1971).
Synthesis of total sterols. The synthesis of cholesterol was
determined by measuring the incorporation of radioactive acetate
into cellular sterols (Corsini et al., 1987; Brown et al., 1978). Cell
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monolayers, after incubation with [2-14C]acetate (1 mCi/ml; specific
activity, 0.9 mCi/mol) for 72 h (see “Miscellaneous protocols”), were
washed with phosphate-buffered saline and digested with 0.1 M
NaOH. Aliquots were saponified at 60°C for 1 h in alcoholic NaOH
after the addition of [1a,2a(n)-3H]cholesterol as internal standard
(0.04 mCi/sample). The nonsaponified material was extracted with
low-boiling petroleum ether and counted for radioactivity. To evalu-
ate the incorporation of labeled acetate into cellular sterols, these
were separated from the nonsaponified fraction by thin-layer chro-
matography with use of petroleum ether (boiling point, 40–60°C)/
diethyl ether/acetic acid (70:30:1). Radioactivity was measured with
Insta-Fluor scintillator cocktail (Packard, Milan, Italy).
Miscellaneous protocols. Cells were seeded at a density of 2 3
105 SMC/Petri dish (35 mm), and incubated with MEM supple-
mented with 10% FCS. Twenty-four hours later, the medium was
changed to one containing 0.4% FCS to stop cell growth, and the
cultures were incubated for 72 h. At this time (time 0), the medium
was replaced with one containing 10% FCS in the presence or ab-
sence of known concentrations of the tested compounds, and the
incubation was continued for a further 72 h at 37°C. At time zero,
just before the addition of the substances to be tested, three Petri
dishes were used for cell counting. Cell proliferation was evaluated
by cell count after trypsinization of the monolayers with use of a
Coulter Counter model ZM (Corsini et al., 1993). Cell viability was
assessed by trypan blue exclusion and found to be higher than 95%
with the concentration of drugs used. In a separate set of Petri
dishes, cholesterol synthesis was estimated under the same experi-
mental conditions by measuring the incorporation of [14C]acetate
into cellular sterols (Corsini et al., 1987, 1993). Proteins were deter-
mined according to Lowry et al. (1951). In another set of experiments,
when extended incubation (9 days) with drugs was required, cells
were seeded at low density (1 3 105 SMC/35-mm Petri dish) so that
linear growth rates could be maintained throughout the duration of
the assay.
The amount of drugs required to inhibit 50% of cholesterol syn-
thesis and of cell proliferation was calculated by linear regression
analysis of the logarithm of the concentrations (mM) versus logit
(Fisher and Yates, 1953).
Statistical data are expressed as mean 6 S.D., except where
otherwise specified. The effects of the tested compounds versus con-
trol on the different parameters were analyzed by two-tailed Stu-
dent’s t test for unpaired data and by Duncan’s test.
Results
To define the role of nonsterol products of MVA in modu-
lation of cell proliferation, a pharmacological approach was
taken. The effect of drugs affecting diverse enzymatic steps of
the MVA pathway on arterial SMC proliferation was inves-
tigated (fig. 1).
Effect of HMG-CoA reductase inhibitors. We previ-
ously demonstrated the ability of simvastatin and fluvastatin
to dose-dependently decrease cholesterol synthesis in SMC
and their proliferation (Corsini et al., 1993, 1995a). To extend
this preliminary observation, we examined the effects of
other HMG-CoA reductase inhibitors on growth and on cho-
lesterol synthesis of cultured SMC. The results show that all
the tested statins, except pravastatin, inhibited arterial myo-
cyte proliferation and cholesterol synthesis dose-depen-
dently. Figure 2 depicts a typical dose-response curve ob-
tained after exposure of cells to statins for 72 h. When statins
were evaluated in human SMC, lower concentrations than
those used in rat SMC were required to inhibit both processes
(Corsini et al., 1993), in agreement with the low HMG-CoA
reductase activity detected in the former cell line (Corsini et
al., 1995b). However, the similar IC50 proliferation/choles-
terol synthesis ratio for all the inhibitory statins (range,
11.7–16.6), regardless of their different potency, supports a
causal relationship between the MVA synthetic pathway and
cell proliferation (Corsini et al., 1993, 1995a, 1996). Analysis
of the data revealed that there was a significant direct cor-
relation between the potency of statins in suppressing cho-
lesterol synthesis and cell proliferation (fig. 3). Pravastatin
at the highest nontoxic concentration inhibited cholesterol
synthesis by ,80% with virtually no detectable effect on
myocyte proliferation (Corsini et al., 1991, 1993, 1995a). Be-
cause pravastatin was unable to completely inhibit sterol
Fig. 1. The MVA pathway. The enzymatic
steps inhibited by the various compounds
used in this study are shown.
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synthesis, shunting MVA away from cholesterol production
may have allowed sufficient endogenous MVA-derived prod-
ucts (dolichols, ubiquinone, isoprenoids) to be formed to sup-
port cell proliferation (Goldstein and Brown, 1990; Maltese,
1990; Glomset et al., 1990).
We previously showed (Corsini et al., 1993, 1995a) that the
addition of MVA, all-trans F-OH or all-trans GG-OH, but not
squalene, restored cell proliferation inhibited by simvastatin
and fluvastatin, which suggested a specific role of isoprenoids
in regulating cell proliferation. We made use of statin-treated
cells as a target cell system to test a variety of known end-
products of the MVA pathway for their ability to counteract
the inhibitory effect of these drugs on cell proliferation. As
shown in figure 4, inhibition of cell growth induced by sim-
vastatin was completely prevented by the addition of MVA
and partially prevented by the addition of all-trans F-OH and
all-trans GG-OH. 2-cis GG-OH, a potential precursor of doli-
chols (Grunler et al., 1994), did not prevent statin blockade of
cell proliferation (fig. 4). These results suggest that dolichols
are not involved in the regulation of cell growth. Squalene
and ubiquinone also failed to restore SMC proliferation in-
hibited by statins. These results support the concept that
SMC require specific isoprenoid metabolites derived from
farnesyl-PP and geranylgeranyl-PP, along with an exogenous
source of cholesterol (FCS), for proliferation. However, MVA,
all-trans GG-OH, 2-cis GG-OH and all-trans F-OH did not
induce cell proliferation in the absence of statins, which
indicated that they were not acting as mitogens (fig. 5).
To investigate the biochemical specificity of statin-induced
inhibition of cell growth and to determine the relative impor-
tance of the various branches of the MVA pathway in pro-
moting cell growth, SMC proliferation and cholesterol syn-
thesis were examined in the presence or absence of metabolic
inhibitors.
Effect of a MVA-PP decarboxylase inhibitor. Because
an early step in the synthesis of isoprenoids is catalyzed by
MVA-PP decarboxylase (Goldstein and Brown, 1990) (fig. 1),
the effect of 6-Fmev, a compound that blocks the conversion
of MVA-PP to isopentenyl-PP (Cuthbert and Lipsky, 1990,
Fig. 2. Effect of L 645–164 on cholesterol synthesis in and proliferation
of rat aorta SMC. Cells were seeded (200 3 103/dish) and incubated
with MEM supplemented with 10% FCS; 24 h later, the medium was
changed with one containing 0.4% FCS to stop cell growth, and the
cultures were incubated for 72 h. At this time (time 0), the medium was
replaced with one containing 10% FCS and the reported concentra-
tions of L 645–164, and the incubation was continued for a further 72 h
at 37°C. 14C-Acetate incorporation was used to assay cholesterol
synthesis, and the cell number provided an index of the effect on cell
replication. Each point represents the mean 6 S.D. of triplicate dishes.
The mean value of the control experiment (without inhibitor) for cell
number was 891 3 103 (64 3 103) cells/plate and for cholesterol
synthesis the mean value was 22.2 6 4.5 pmol/mg cell protein per hour;
these mean values are designed as 100%. Error bars not shown are
within the symbol limits. Inhibitor versus control: ** P , .01; *** P , .001
(Student’s t test).
Fig. 3. Linear regression analysis of IC50 values for proliferation of and
cholesterol synthesis in aorta SMC after incubation with statins (r2 5
.98; P , .001). IC50 5 concentration of drug required to inhibit choles-
terol synthesis and cell proliferation by 50%. Data from references
Corsini et al. (1993)a and Corsini et al. (1996).b
Fig. 4. Ability of MVA and its derivatives to prevent inhibition of rat
aorta SMC proliferation by simvastatin. Experimental conditions are as
in figure 2. Each bar represents the average of at least triplicate exper-
iments, the results of which differed by ,10%. The mean value of
control experiments (1) (without inhibitor) was 1243 3 103 (647 3 103)
cells/plate and is designed as 100%. Duncan’s test (P , .05): 3 versus
4, 5; (P , .01): 1 versus 2, 3, 4, 5, 6, 7; 2 versus 4, 6, 7, 8; 3 versus 6,
7, 8; 4 versus 5, 6, 7, 8; 5 versus 6, 7, 8; 6 versus 7; 7 versus 8. M 5
simvastatin 3.5 mM (2); o 5 ubiquinone 30 mM (3); u 5 squalene 10 mM
(4); p 5 2-cis GG-OH 5 mM (5); z 5 all-trans GG-OH5 mM (6); d 5
all-trans F-OH 10 mM (7); t 5 MVA 100 mM (8).
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1991; Dhe-Paganon et al., 1994; Nave et al., 1985) and thus
acts distal to statins, was examined. 6-Fmev inhibited the
proliferation of, and cholesterol synthesis in cultured myo-
cytes in a dose-dependent manner (fig. 6). These results also
indicate that the compound displayed similar potency in in-
hibiting both cellular processes with IC50 values of 6.7 and
10.8 mM for proliferation and cholesterol synthesis, respec-
tively. The failure of MVA, but not of all-trans F-OH and
all-trans GG-OH, to partially promote myocyte replication in
the presence of 6-Fmol (fig. 7) indicates that its effect is
related, at least in part, to the inhibition of isoprenoid bio-
synthesis. Although the mechanism by which 6-Fmol inter-
feres with cell proliferation is rather complex (Cuthbert and
Lipsky, 1991), the present results confirm the specific role of
isoprenoids in regulating cellular growth.
Farnesyl-PP plays a central role in the MVA pathway
because it is the last common substrate for the synthesis of
all the end-products (Grunler et al., 1994) (fig. 1). Therefore,
the so-called branch-point enzymes that use farnesyl-PP rep-
resent potential pharmacological targets for further address-
ing the role of the MVA pathway in cell proliferation.
Effect of squalene synthase and epoxidase inhibi-
tors. Selective inhibitors of squalene synthase, the first com-
mitted enzyme in the cholesterol biosynthetic pathway
(Grunler et al., 1994), and of squalene epoxidase were inves-
tigated. Treatment of cells with squalestatin 1, a specific
competitive inhibitor of squalene synthase (Baxter et al.,
1992), blocked cholesterol synthesis and slightly inhibited
(21% decrease) SMC proliferation only at the highest tested
concentration (fig. 8). NB-598, a squalene epoxidase inhibitor
(Horie et al., 1990), caused complete inhibition of cholesterol
synthesis without affecting the proliferation of SMC grown in
the presence of exogenous cholesterol (fig. 9). Hence, involve-
ment of the sterol branch of farnesyl-PP metabolism in the
control of cell proliferation was obviated.
Effect of a PFTase inhibitor. To directly address the
role of all-trans F-OH availability for cell proliferation, the
effect of PFTase inhibitor on cell growth was examined. Cells
were seeded at low density and allowed to grow for 9 days in
the absence or presence of various concentrations of the spe-
cific inhibitor of PFTase BZA-5B (James et al., 1993). In the
absence of the inhibitor, arterial myocytes grew logarithmi-
cally (fig. 10). In the presence of BZA-5B, growth of myocytes
was inhibited in a time- and dose-dependent manner, reach-
ing '60% inhibition after 9 days in the presence of 50 mM
Fig. 5. Effect of MVA, all-trans F-OH, all-trans GG-OH and 2-cis
GG-OH on proliferation of rat aorta SMC. Experimental conditions are
as in figure 2. Each point represents the mean 6 S.D. of triplicate
dishes. The mean value of control experiment for cell number was
563 3 103 (6 19 3 103) cells/plate and is designed as 100%. M 5 MVA
100 mM; u 5 all-trans F-OH 10 mM; z 5 all-trans GG-OH 5 mM; 5
2-cis GG-OH 5 mM.
Fig. 6. Effect of 6-Fmev on cholesterol synthesis in and proliferation of
rat aorta SMC. Experimental conditions are as in figure 2. Each point
represents the mean 6 S.D. of triplicate dishes. The mean value of the
control experiment (without inhibitor) for cell number was 1399 3 103
(6104 3 103) cells/plate and for cholesterol synthesis the mean value
was 92.5 6 4.5 pmol/mg cell protein per h; these mean values are
designed as 100%. Inhibitor versus control: ** P , .01, *** P , .001
(Student’s t test).
Fig. 7. Ability of MVA, all-trans F-OH and all-trans GG-OH to prevent
inhibition of rat aorta SMC proliferation by 6-Fmev. Experimental con-
ditions are as in figure 2. Each point represents the mean 6 S.D. of
triplicate dishes. The mean value of control experiment was 1013 3 103
(685 3 103) cells/plate and is designed as 100%. Student’s t test: **
P , .01 all-trans F-OH versus 6-Fmev; *** P , .001 all-trans GG-OH
versus 6-Fmev. M 5 6-Fmev 10 mM; o 5 6-Fmev 1 MVA 100 mM; z 5
6-Fmev 1 all-trans F-OH 10 mM; s 5 6-Fmev 1 all-trans GG-OH 5 mM.
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BZA-5B (fig.10). Under parallel experimental conditions, this
PFTase inhibitor had no effect on cholesterol synthesis (93%
of the control value). In experiments of 3 days duration,
BZA-5B (100 mM) inhibited the growth of SMC by 60% (fig.
11). Similar concentrations of BZA-5B have been reported to
inhibit the growth of H-ras-transformed cells (James et al.,
1993). The addition of all-trans GG-OH restored cell prolif-
eration to control levels, whereas MVA, but not all-trans
F-OH, partially prevented the inhibitory effect of BZA-5B
(fig. 11). The proliferation was not affected when cells were
grown with an inactive inhibitor analog, BZA-7B (fig. 11)
(James et al., 1994), which is identical to BZA-5B except for
a serine in place of a cysteine. Taken together, these results
implicate the involvement of prenylated protein(s) in regu-
lating cell proliferation.
Discussion
A major focus of the current studies is the identification of
a nonsterol MVA derivative(s) whose presence in cells corre-
lates with cell proliferation. Four experiments substantiate
the relationship between all-trans F-OH, all-trans GG-OH
(probably through one or more prenylated proteins) and rates
of cell growth.
First, MVA, all-trans F-OH and all-trans GG-OH are all
able to prevent the inhibition of SMC proliferation induced
by statins (Corsini et al., 1993). The observation that the
antiproliferative effect of statins occurs when cholesterol syn-
thesis is suppressed by more than 80%, supports a causal
relationship between the MVA pathway and cell proliferation
(Corsini et al., 1993, 1995b; Parker et al., 1990). These find-
ings suggest that strong inhibition of MVA production elic-
ited by statins might impede sufficient formation of endog-
enously derived products (fig. 1) to support cell proliferation.
Fig. 8. Effect of squalestatin 1 on cholesterol synthesis in and prolif-
eration of rat aorta SMC. Experimental conditions are as in figure 2;
fresh solutions of squalestatin 1 are re-added to the culture medium
every 24 h. Each point represents the mean 6 S.E. of three experi-
ments, each run in triplicate. The mean value of the control experiments
(without inhibitor) for cell number was 1556 3 103 (645 3 103) cells/
plate and for cholesterol synthesis the mean value was 15.5 6 1.1
pmol/mg cell protein per h; these mean values are designed as 100%.
Error bars not shown are within the symbol limits. Inhibitor versus
control: ** P , .01, *** P , .001 (Student’s t test).
Fig. 9. Effect of NB-598 on cholesterol synthesis in and proliferation of
rat aorta SMC. Experimental conditions are as in figure 2. Each point
represents the mean 6 S.E. of three experiments, each run in triplicate.
The mean value of the control experiment (without inhibitor) for cell
number was 1057 3 103 (662 3 103) cells/plate and for cholesterol
synthesis the mean value was 24.2 6 2.2 pmol/mg cell protein per h;
these mean values are designed as 100%. Inhibitor versus control:
* P , .05, ** P , .01 (Student’s t test).
Fig. 10. Effect of BZA-5B on proliferation of rat aorta SMC. Cells were
seeded (100 3 103) and incubated with Eagle’s MEM supplemented
with 10% FCS; 24 h later the medium was changed with one containing
0.4% FCS to stop cell growth and the cultures were incubated for 72 h.
At this time (time 0, cell number 5 322 3 103/dish), the medium was
replaced with one containing 10% FCS and the reported concentra-
tions of BZA-5B, and the incubation was continued for 3, 5 and 9 days,
respectively. On days 3 and 5, cells were re-fed with the same medium.
Each point represents the mean 6 S.D. of triplicate dishes. Error bars
not shown are within the symbol limits. Inhibitor versus control:
* P , .05, ** P , .01, *** P , .001 (Student’s t test). M 5 control;
o 5 simvastatin 5 mM (3 days); o 5 simvastatin 1 mM (5, 9 days);
u 5 BZA-5B 10 mM; p 5 BZA-5B 25 mM; z 5 BZA-5B 50 mM.
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One critical end-product of MVA is cholesterol that is re-
quired for cell membrane formation in proliferating cells
(Goldstein and Brown, 1990; Chen, 1984; Grunler et al.,
1994). It is unlikely, however, that inhibition of cholesterol
synthesis explains the action of statins on SMC proliferation.
In fact, cells are stimulated to grow by exposure to a medium
containing 10% FCS, which provides an exogenous source of
cholesterol, and under such conditions, statins still inhibit
cell proliferation. Recently, several proteins that are involved
in growth factor signal transduction have been shown to be
lipid-modified by the covalent attachment of farnesyl-PP and
geranylgeranyl-PP groups, which are derived from MVA
(Goldstein and Brown, 1990; Fairbanks et al., 1984; Farn-
sworth et al., 1990; Casey et al., 1989). Statins inhibit the
biosynthesis of these two isoprenoids, and one possible mech-
anism by which they affect cell growth may be the interfer-
ence with signaling pathways that require prenylated pro-
teins. The fact that all-trans GG-OH and all-trans F-OH can,
under these experimental conditions, partially prevent sta-
tin-induced inhibition of cell growth in the absence of other
prenyl intermediates, suggests that proteins modified by
these isoprenoids are necessary for cell proliferation. In ad-
dition, it was shown that both labeled all-trans F-OH and
labeled all-trans GG-OH are readily incorporated into cellu-
lar proteins and other metabolites made from prenyl-PP,
which thus supports our experimental approach (A. Corsini,
C. C. Farnsworth, P. McGeady, M. H. Gelb and J. A. Glomset,
manuscript in preparation; Crick et al., 1994, 1995; Danesi et
al., 1995).
Ubiquinone, 2-cis GG-OH (a potential precursor of doli-
chols) and squalene failed to overcome the inhibitory effect of
statins; this rules out the possibility that the putative regu-
lator(s) of cell proliferation is one of these products of the
MVA pathway. Another MVA-derived isoprenoid, isopente-
nyl adenosine, was also investigated. Unfortunately, this
product, like many adenosine derivatives, is often toxic for
mammalian cells (Mittelman et al., 1975) and causes cell
death. However, when assayed in several cultured cells, iso-
pentenyl adenosine was unable to prevent the antiprolifera-
tive effect of statins (Perkins et al., 1982; Sinensky and Logel,
1985; Larsson and Zetteberg, 1986; Munro et al., 1994).
The failure of ubiquinone, dolichols, isopentenyl adenosine
and squalene to prevent the inhibitory effect of statins on cell
proliferation has been reported (Faust and Dice, 1991; Wejde
et al., 1993; Corsini et al., 1993; O’Donnell et al., 1993). The
present data do not exclude the possibility that other isopre-
noid products may also be involved in cell proliferation. We-
jde et al. (1993) found that an unidentified MVA-derived lipid
component, which coeluted with dolichol, completely restored
DNA synthesis in lovastatin-treated cells.
Because several different products of the MVA pathway
are essential elements in several cellular processes (Gold-
stein and Brown, 1990; Grunler et al., 1994), it seems likely
that different isoprenoid requirements may be revealed un-
der different experimental conditions. For example, Doyle et
al. (1993) have shown that cells arrested in growth by MVA
depletion behave differently from cells synchronized by se-
rum depletion. Under their experimental conditions, dolichol
phosphates and its glycosylated derivatives were the MVA-
derived compounds limiting cellular growth. Further under-
standing of the roles of different isoprenoids in cell prolifer-
ation requires a deeper knowledge of the cellular processes
regulating the levels of isoprenoids and their functional di-
versity.
The second approach for understanding the relationship
between isoprenoid metabolism and cell proliferation makes
use of 6-Fmev. This compound (Nave et al., 1985; Reardon
and Abeles, 1987) is a useful pharmacological tool for exam-
ining the role played in cell proliferation by MVA derivatives
just downstream of MVA-PP decarboxylase. When the decar-
boxylation of MVA-PP to isopentenyl-PP was blocked by
6-Fmev, both cholesterol synthesis and SMC growth were
inhibited in a dose-dependent manner. Unlike statins, this
drug inhibits cholesterol synthesis and cell growth with sim-
ilar potency, which implies different antiproliferative mech-
anisms. It has been proposed recently that 6-Fmev inhibits
the proliferation of cells by two distinct but related mecha-
nisms (Cuthbert and Lipsky, 1990, 1991; Sawamura et al.,
1993). By inhibition of isoprenoid synthesis, 6-Fmev sup-
presses SMC proliferation, and this effect was partially pre-
vented by providing an exogenous source of all-trans F-OH
and all-trans GG-OH. The other mode of action appears to
result from the accumulation of an inhibitory group of me-
tabolites derived from MVA or one of its phosphates. Our
results, together with these previous observations (Cuthbert
and Lipsky, 1990, 1991; Sawamura et al., 1993), indicate that
MVA is a critical determinant of cellular proliferation be-
cause it is a source of both positive and negative regulatory
influences.
In a third approach, the contribution of de novo sterol
synthesis in the control of cell proliferation was studied with
squalene synthase and squalene epoxidase inhibitors. These
enzymes catalyze steps committed to the sterol synthetic
pathway (Goldstein and Brown, 1990; Grunler et al., 1994)
and thus represent ideal sites for selectively inhibiting sterol
Fig. 11. Effect of BZA-5B, BZA-7B, MVA and its derivatives on prolif-
eration of rat aorta SMC. Experimental conditions are as in figure 10.
Cells were incubated with the tested compounds for 72 h. Each point
represents the mean 6 S.D. of triplicate dishes. The mean value of the
control experiment (without inhibitor) for cell number was 416 3 103
(620 3 103) cells/plate and is designed as 100%. Duncan’s test: P ,
.05, MVA versus control; P , .01, BZA-5B versus control, MVA, all-trans
GG-OH; P , .01, all-trans F-OH versus control, MVA, all-trans GG-OH.
M 5 BZA-5B 100 mM; o 5 BZA-5B 1 all-trans GG-OH 2.5 mM; s 5
BZA-5B 1 all-trans F-OH 10 mM; p 5 BZA-5B 1 MVA 100 mM; z 5
BZA-7B 100 mM.
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formation, hence addressing the involvement of the sterol
branch in cell growth. The administration of squalestatin 1
(Baxter et al., 1992) dose-dependently inhibited cholesterol
synthesis and slightly inhibited (25 mM) SMC growth. It is
noteworthy to mention that squalestatin inhibits ras PFTase,
although with much less potency (Dufresne et al., 1993;
Gibbs et al., 1993), and this could explain its effect on SMC
growth. Unlike statins, concentrations of squalestatin 1 that
completely blocked cholesterol synthesis (5–10 mM) did not
affect cell proliferation. These findings are in agreement with
a previous study by Bradfute et al. (1992), which showed a
normal rate of growth of a squalene synthase-deficient mu-
tant CHO cell line in a medium supplemented with serum,
and with the inability of squalene to prevent the inhibitory
effect of statins on cell proliferation (Wejde et al., 1993;
Corsini et al., 1993, 1995a; Keyomarsi et al., 1991). NB-598
(Horie et al., 1990) specifically inhibited cholesterol synthesis
without affecting SMC growth, thus ruling out a role of
squalene or any distal intermediate of the cholesterol syn-
thetic pathway in cell proliferation.
Finally, a direct link between the inhibition of cell prolif-
eration and protein prenylation is apparent. The involve-
ment of prenylated proteins in cell growth (Maltese, 1990;
Glomset et al., 1990; Jakobisiak et al., 1991; Casey et al.,
1994) is given further credence by results obtained with
BZA-5B. This drug is a potent and specific inhibitor of
PFTase (James et al., 1993) and a selective antagonist of
H-ras transformed cells (James et al., 1994, 1995), probably
through inhibition of ras-dependent cell growth (James et al.,
1993, 1994, 1995). The requirement for prolonged incubation
of cultured SMC with BZA-5B to induce an antiproliferative
effect is consistent with the specificity of the compound for
ras (James et al., 1994, 1995), a protein with a very long
half-life (20–56 h) (Ulsh and Shih, 1984). Probably because of
inefficient cell penetration (Gibbs et al., 1994), high concen-
trations (10–100 mM) of BZA-5B are required to detect any
significant inhibitory effect on cell growth (James et al.,
1993). Two sets of control experiments address the issue of
the specificity of the effect of BZA-5B in SMC cells. First, the
effect of the PFTase inhibitor on SMC proliferation was not
observed by the structurally related compound BZA-7B,
which does not inhibit PFTase (James et al., 1994). Second,
MVA and all-trans GG-OH, but not all-trans F-OH, partially
prevent the inhibitory effect of BZA-5B on cell proliferation.
This result may be caused by the fact that PGGTase I is able
to geranylgeranylate but not farnesylate proteins that nor-
mally serve as farnesyl acceptors (Armstrong et al., 1995;
Yokoyama et al., 1995). It is tempting to speculate that PG-
GTase I can geranylgeranylate mitogenic proteins that are
normally modified by the all-trans F-OH moiety, such as
K-ras, in a reaction that is relatively resistant to inhibition
by BZA-5B (Armstrong et al., 1995). Previous studies have
shown that geranylgeranylated ras proteins support trans-
formation of animal cells (Cox et al., 1992) and growth of
yeast cells (Trueblood et al., 1993). Testing of this hypothesis
will require antibodies that recognize K-ras at the low con-
centrations that are present in normal animal cells; these
antibodies are not yet available. The possibility also exists
that geranylgeranylated proteins of the rho-family (Vincent
et al., 1992; Olson et al., 1995; Vojtek and Cooper, 1995) and
rap (Quarck et al., 1994) may compensate for ras in growth
factor signal transduction pathway and in the control of cell
proliferation. One surprising result is the ability of BZA-5B
to inhibit cell growth of untransformed SMC. It has been
reported that normal fibroblasts continue to grow in the
presence of the PFTase inhibitor at concentrations that
markedly slow the growth of H-ras-transformed cells (Lowy
and Willumsen, 1995; James et al., 1993). Several aspects of
ras function may contribute to this resistance of untrans-
formed cells to the effect of PFTase inhibitors (Lowy and
Willumsen, 1995; Marshall, 1995). It seems likely that un-
transformed fibroblasts may produce forms of ras (K-ras or
N-ras) whose farnesylation is relatively resistant to BZA-5B,
or that are geranylgeranylated (James et al., 1994, 1996;
Mumby et al., 1990). The possibility also exists that fibro-
blasts can respond to mitogenic stimuli through pathways
that bypass ras. This hypothesis is consistent with recent
evidence showing that growth factors can activate transcrip-
tion factors via a ras-independent mechanism (Sepp-Loren-
zino et al., 1995; Heim, 1996; Pumiglia et al., 1995; Inglese et
al., 1995). On the other hand, the observation of an induction
of H-ras protooncogene expression in proliferating rat SMC
(Sadhu and Ramos, 1993), together with the recent demon-
stration that the local delivery of transdominant negative
H-ras mutants inhibits proliferation after balloon injury of
rat carotid artery (Indolfi et al., 1995), indicates a role of
H-ras as a key transducer of mitogenic signals in vascular
myocytes. The abundance of available data demonstrates
that mitogenic signaling in SMC is complex and an overlap-
ping of signaling elements can be induced by hormones and
growth factors through G protein-coupled serpentine recep-
tors as well as receptor tyrosine kinases (Ludwig and Rapp,
1995).
The ability of BZA-5B to inhibit SMC proliferation high-
lights the potential usefulness of compounds that block the
action of key components of the mitogenic signaling cascade
for therapy of vascular proliferative disorders, such as ath-
erosclerosis and restenosis after angioplasty (Corsini et al.,
1995a; Ross, 1993). PGGTase I specific inhibitors (Lerner et
al., 1995) have not yet been investigated, and the role of
geranylgeranylated proteins in controlling cell proliferation
still remains to be directly addressed.
In conclusion, the results presented in this paper demon-
strate the importance of the MVA pathway in cell prolifera-
tion. These studies reveal the involvement of the specific
isoprenoid metabolites farnesyl-PP and geranylgeranyl-PP,
which are necessary for the prenylation of one or more pro-
teins that are involved in regulation of cell proliferation.
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